US.MRNA · Moderna

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 7.962698215774139,
        "turnoverUsdM": 4066.213678233966,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 203.5278,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 15.9,
      "take_profit_price": 298.6232,
      "target_multiplier": 2.2,
      "technical_strength": 2,
      "take_profit_percent": 23.4
    },
    "positionPoints": 1.1,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.5599999999999998,
    "stopLossPercent": 15,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 77.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 18
  },
  "market": {
    "ma20": 206.8495,
    "ma50": 161.933,
    "close": 242.08,
    "prevClose": 226.89,
    "avgVolume20": 17878934,
    "volumeRatio": 0.94,
    "changePercent": 6.69
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 18,
    "details": {
      "ret_5d": 0.11944509595375719,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 18,
      "vcp_bonus": 0,
      "vol_ratio": 0.9208478475152927,
      "ret_points": 16,
      "vol_points": 0,
      "range_ratio": 1.3654979475775992,
      "volat_points": 2,
      "day_range_pct": 0.11289160514795435,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 77.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 17.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 86,
        "contribution": 17.2
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 53,
        "contribution": 5.3
      },
      {
        "raw": 21.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72,
        "contribution": 21.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 59.9,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 17.2/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.3/10分",
      "技術信號分析總分: 21.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 17.2,
      "市場環境": 5.4,
      "情緒分析": 6,
      "技術信號": 21.6,
      "風險管理": 5.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 4066.213678233966,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.44
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 739.87200315,
                "ma50": 726.61519988,
                "name": "QQQ",
                "close": 717.63,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.61649505,
                "ma50": 768.28659516,
                "name": "SPY",
                "close": 769.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 7.962698215774139,
          "atrPoints": 1,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142962591,
                "url": "https://finnhub.io/api/news?id=1bb2249de9a239eeea010dbc1202e9c3d4d7dde3eff82ace0c6a353fb6a688de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.",
                "category": "company",
                "datetime": 1792255380,
                "headline": "Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline"
              },
              {
                "id": 142959205,
                "url": "https://finnhub.io/api/news?id=35d2528b6f45127bfd2262dd5afe7c59219686e8daef1a82ac77cbc7871d0c8e",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 gap downs on October 16 include MRNA, TWLO, COHR, STX, SMCI, WDC, SNDK, P, FLEX and PANW, with declines carrying into the session.",
                "category": "company",
                "datetime": 1792161400,
                "headline": "S&P 500 Gap Downs on October 16: MRNA, TWLO and COHR Lead Declines"
              },
              {
                "id": 142928564,
                "url": "https://finnhub.io/api/news?id=eafe019c62ce64669af4574e6e975ab26ea081c2dd6074fd2f03985d0eaf7773",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s upcoming cancer vaccine data, Coca-Cola’s new KFC beverage partnership and Visa’s expanding services business stoked investor interest.",
                "category": "company",
                "datetime": 1792120729,
                "headline": "Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today?"
              },
              {
                "id": 142921517,
                "url": "https://finnhub.io/api/news?id=8c3da465e9e0bdb90c7940172faecbe1878e4269fe6803587001c2961d490742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral rating.",
                "category": "company",
                "datetime": 1792093362,
                "headline": "MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data"
              },
              {
                "id": 142852474,
                "url": "https://finnhub.io/api/news?id=288e96a0f39976996dc6855674ee391f80bb8691dcb257d54e15af7043c4f3ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?",
                "category": "company",
                "datetime": 1791903660,
                "headline": "MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142824630,
                "url": "https://finnhub.io/api/news?id=43df23e601f4825f694952c4d6c8d28928860c31593421aec5e57e82831752db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791838203,
                "headline": "Here's Why Moderna (MRNA) Fell More Than Broader Market"
              },
              {
                "id": 142821797,
                "url": "https://finnhub.io/api/news?id=101e25e7c4ca9a920679bb28ba1c583059215c31ea63222d3ce3d0ee418bae7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and human control concerns dominated recent industry discussions, the quarterly letter highlights the massive, untapped potential of deploying existing AI capacity into industrial applications. The letter […]",
                "category": "company",
                "datetime": 1791815227,
                "headline": "Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally"
              },
              {
                "id": 142811129,
                "url": "https://finnhub.io/api/news?id=aa4e6af2649f3f9eeb6605ff7b67664cda878a49a5317f2d94fbdf632020f8e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The rallies highlighted growth opportunities across biotechnology, health insurance and optical technology.",
                "category": "company",
                "datetime": 1791774188,
                "headline": "Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week?"
              }
            ],
            "raw_source": [
              {
                "id": 143032268,
                "url": "https://finnhub.io/api/news?id=48a2cbbf1adbc6051988163a49e8a13292fcdfc3889377530faed9172a32a040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.",
                "category": "company",
                "datetime": 1792528510,
                "headline": "OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business"
              },
              {
                "id": 143031687,
                "url": "https://finnhub.io/api/news?id=9767c866ea027121f6e583a1c9d55c71caf1930dcf32f3011cf51a1089f09880",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.",
                "category": "company",
                "datetime": 1792523164,
                "headline": "S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall"
              },
              {
                "id": 143032118,
                "url": "https://finnhub.io/api/news?id=5706a549de19317028a89a3d0711c22462e81539f7468dfc667f38a79817cba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 Health Care Sector was on track to set a fresh closing high, leading Tuesday's broad market gains.",
                "category": "company",
                "datetime": 1792521676,
                "headline": "The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge."
              },
              {
                "id": 143031303,
                "url": "https://finnhub.io/api/news?id=c73fde257ce933701e64d302334df56883dce8baee224a95a5f24da1e2b346cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .",
                "category": "company",
                "datetime": 1792521344,
                "headline": "OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports"
              },
              {
                "id": 143030218,
                "url": "https://finnhub.io/api/news?id=e747848b56e46bf9d01a9ff03a13dec6283182b4d2d7bed43caec00c1f2ac2c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.",
                "category": "company",
                "datetime": 1792518806,
                "headline": "Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%"
              },
              {
                "id": 143030337,
                "url": "https://finnhub.io/api/news?id=3e6d62cb4307762cc24d905acd825a8cb960483374497293a3308d0fc618ca8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Everest Medicines recently appointed Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, to lead global mRNA therapeutic development and align U.S. and China research teams. The hire brings direct experience from Moderna and other major biopharma groups in mRNA cancer vaccines and translational immuno-oncology, which could influence how Everest Medicines executes on its proprietary mRNA platform and broader pipeline. We will now assess how Everest Medicines'...",
                "category": "company",
                "datetime": 1792516670,
                "headline": "Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?"
              },
              {
                "id": 143027729,
                "url": "https://finnhub.io/api/news?id=a141060e79ad532325fb6aae42841b3f8307b37d1ac4af485f1ac9fafc450e75",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1792491293,
                "headline": "Moderna: Sell The Cancer Vaccine Hype"
              },
              {
                "id": 143011453,
                "url": "https://finnhub.io/api/news?id=10c4037b3f6f104f99d09839a8c3778e12c0fa7c38338132c3f43a56b7735375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.",
                "category": "company",
                "datetime": 1792447255,
                "headline": "Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know"
              },
              {
                "id": 143013695,
                "url": "https://finnhub.io/api/news?id=1de04184caa4d14b46eb85351a1a67146ab51409cb067786b2cc413c137ce9f7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers for the Oct. 19, 2026 US session: DDOG led gainers at 6.2%, while MOS led losers at -4.65%.",
                "category": "company",
                "datetime": 1792436758,
                "headline": "S&P 500 Top Movers: Oct. 19, 2026 US Session Gainers and Losers"
              },
              {
                "id": 143013693,
                "url": "https://finnhub.io/api/news?id=cd590db40b7a91aa3c4b8aa1a584864cd72c49faa7cc4e1886a0d56716410d7e",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Palantir rose 5.05% and Ford fell 2.25% among the most active S&P 500 stocks on Oct. 19, with volume in each name below its 50-day average.",
                "category": "company",
                "datetime": 1792433162,
                "headline": "Most Active S&P 500 Stocks on Oct. 19"
              },
              {
                "id": 143010815,
                "url": "https://finnhub.io/api/news?id=65f6955d7e37181274569549bd08ac674281fe8c8e15222005245f3364c8ead6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334907481/image_1334907481.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "US equity markets faced significant selling pressure this week, with sharp declines in tech and growth-oriented stocks contrasting with strong gains across defensive, energy, and value.",
                "category": "company",
                "datetime": 1792426200,
                "headline": "ValuEngine Weekly Market Commentary"
              },
              {
                "id": 143028818,
                "url": "https://finnhub.io/api/news?id=d2778ab90b572efff5219eab520a5e44a8c50826e9b43bcac8c54fbcaed07099",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "AI-driven \"biointelligence\" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.",
                "category": "company",
                "datetime": 1792420200,
                "headline": "The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning"
              },
              {
                "id": 143006918,
                "url": "https://finnhub.io/api/news?id=5f336665f9fa1a7eb4c3fcdb242bbff8b8de8f6d4386c92b570badeb9c797fba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 25.2% gain over the past six months, beating the S&P 500 by 16.3 percentage points.",
                "category": "company",
                "datetime": 1792416535,
                "headline": "3 Healthcare Stocks That Concern Us"
              },
              {
                "id": 143007833,
                "url": "https://finnhub.io/api/news?id=65f854f318ee8ec9355143f0bb74dbc72dbee90babc38adefbe1c714c3590c6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/19/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.",
                "category": "company",
                "datetime": 1792406274,
                "headline": "What's Going On With Moderna Stock Monday?"
              },
              {
                "id": 142992182,
                "url": "https://finnhub.io/api/news?id=76496f81480358631a4fdb5349265ccf7219ba4e626da0d1745c468f7b418512",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.",
                "category": "company",
                "datetime": 1792379713,
                "headline": "Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In"
              },
              {
                "id": 142990503,
                "url": "https://finnhub.io/api/news?id=72a381499b808a00216df9a7b830934afd347818d96ba9c1ce2e8eaadba820a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences has delivered a very strong multi year share price run, which now puts a spotlight on whether the current market value lines up with what its balance sheet actually supports. With that backdrop, the live question for you is how well the stock price today lines up with Roivant Sciences' book value. Over the past 5 years the stock has returned about 393%, which puts real weight on the question of how much book value is backing each dollar of market value today. Progress toward...",
                "category": "company",
                "datetime": 1792369212,
                "headline": "Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run"
              },
              {
                "id": 142988608,
                "url": "https://finnhub.io/api/news?id=981c4939bb12dccff9bebb22223c1a799ab1e82b029f1359f5435ffb1584a732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It has been a volatile year for the biotech.",
                "category": "company",
                "datetime": 1792349520,
                "headline": "Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?"
              },
              {
                "id": 142986896,
                "url": "https://finnhub.io/api/news?id=df82a56df15e90495c351ce929d7cbf38d5fb8c6da4a97e9263335a6b8ff7f6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It was a head-turning headline. Here's why the market was buzzing.",
                "category": "company",
                "datetime": 1792328700,
                "headline": "Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors."
              },
              {
                "id": 142971284,
                "url": "https://finnhub.io/api/news?id=417b4fb879081d5ade679677727209b51e3c42110dee2814fafd701b1119a294",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Sandisk is changing its business model to reduce its cyclicality.",
                "category": "company",
                "datetime": 1792302600,
                "headline": "Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?"
              },
              {
                "id": 142962591,
                "url": "https://finnhub.io/api/news?id=1bb2249de9a239eeea010dbc1202e9c3d4d7dde3eff82ace0c6a353fb6a688de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.",
                "category": "company",
                "datetime": 1792255380,
                "headline": "Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline"
              },
              {
                "id": 142958499,
                "url": "https://finnhub.io/api/news?id=b1420296c8a567dcd40c8432fd47e28578939718a62fe248eb6f1b4c039ba42a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...",
                "category": "company",
                "datetime": 1792210915,
                "headline": "Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock"
              },
              {
                "id": 142951534,
                "url": "https://finnhub.io/api/news?id=a6ec6823402e68ad6ddd5bb35f18a9ec64b21a46ee6a9622a167015e67770089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792183740,
                "headline": "Moderna Stock Slumps, but It’s Too Early to Panic"
              },
              {
                "id": 142950922,
                "url": "https://finnhub.io/api/news?id=3d84b14e70e8d6a49ca4956cbf56c9fe1e46b415cf9dac770ae6bfdec6d22e0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk.",
                "category": "company",
                "datetime": 1792183419,
                "headline": "Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know"
              },
              {
                "id": 142952846,
                "url": "https://finnhub.io/api/news?id=5922d94a3abed12c8a3406d8ca67edcda453c5c0dbf98dc4e8c91e66fad73146",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191725662/image_2191725662.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Nasdaq loses 4% on the week. WTI crude settles over $101 per barrel. Inflation worries climb but FedWatch tool stays steady",
                "category": "company",
                "datetime": 1792182000,
                "headline": "Tough Trading Leaves Indices In The Red"
              },
              {
                "id": 142950824,
                "url": "https://finnhub.io/api/news?id=74963cb0e70ab8059f861c09846021096b759eb7a9602add0dbe79b1eea9591b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792179360,
                "headline": "Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather"
              },
              {
                "id": 142959212,
                "url": "https://finnhub.io/api/news?id=1623819f3bfa1555899d10dbc1cb3e08c5703c2ee3ac84cc9b6bc50bda3f12b0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Today's S&P 500 top movers include FANG, EOG, EQT, APA, NI, HONA, TRGP, KMI, RTX and NOC among gainers, while TWLO, MRNA, SMCI, DDOG and PANW lead decliners.",
                "category": "company",
                "datetime": 1792177598,
                "headline": "S&P 500 Top Movers: Today's Gainers and Losers"
              },
              {
                "id": 142959210,
                "url": "https://finnhub.io/api/news?id=b3986a48a3f5afab657ba95ce3d87f80df82d15165f29bb14aad7f91ddb88834",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 most-active stocks for Oct. 16, 2026: SMCI, F, BAC, T, PLTR, NKE, ORCL, HPE, MRNA, and PFE saw heavy volume, with sharp declines and modest gains.",
                "category": "company",
                "datetime": 1792173976,
                "headline": "Most-Active S&P 500 Stocks in Oct. 16, 2026 US Session"
              },
              {
                "id": 142949190,
                "url": "https://finnhub.io/api/news?id=c959e477e65a218a0cad05f9bd494251447e606cfc31fc5528eee170530d7ad3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.",
                "category": "company",
                "datetime": 1792169050,
                "headline": "Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady"
              },
              {
                "id": 142959207,
                "url": "https://finnhub.io/api/news?id=71b17cbd30cf9aa4ef3c77c0f458131845b037c6290603b9f3dd4fe992b04de2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers today: HONA, EOG, EXE, NI, EQT, MSI, BKR, KMI, IDXX and SLB gained, while TWLO, MRNA, SMCI, CRWD, FTNT, DDOG, PLTR, COHR, FLEX and STX declined.",
                "category": "company",
                "datetime": 1792168603,
                "headline": "S&P 500 Top Movers Today: HONA Tops Gainers, TWLO Tops Decliners"
              },
              {
                "id": 142948002,
                "url": "https://finnhub.io/api/news?id=e586d9fa75f4bb019a822871751834ee14425871a48920ab8652e36bf3d86a7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.",
                "category": "company",
                "datetime": 1792164153,
                "headline": "Moderna stock sinks as Wall Street turns cautious following blistering rally"
              },
              {
                "id": 142948003,
                "url": "https://finnhub.io/api/news?id=9dbc95242c8d52265d5c0557a75bf5612f2300b046560659575730db61480277",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.",
                "category": "company",
                "datetime": 1792162163,
                "headline": "Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put"
              },
              {
                "id": 142948004,
                "url": "https://finnhub.io/api/news?id=3baf1ee24e890652fecbebc36de430f14066942b4fdd1616633ea9c823267896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri",
                "category": "company",
                "datetime": 1792161868,
                "headline": "What Is The Case For Waiting On Moderna Stock?"
              },
              {
                "id": 142959205,
                "url": "https://finnhub.io/api/news?id=35d2528b6f45127bfd2262dd5afe7c59219686e8daef1a82ac77cbc7871d0c8e",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 gap downs on October 16 include MRNA, TWLO, COHR, STX, SMCI, WDC, SNDK, P, FLEX and PANW, with declines carrying into the session.",
                "category": "company",
                "datetime": 1792161400,
                "headline": "S&P 500 Gap Downs on October 16: MRNA, TWLO and COHR Lead Declines"
              },
              {
                "id": 142945790,
                "url": "https://finnhub.io/api/news?id=00513baefbcedcb0ae3d13be5f7cb7180d45cac25350ea2e4b7eaad81dda4528",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.",
                "category": "company",
                "datetime": 1792156500,
                "headline": "This week in charts: Moderna’s massive stock run"
              },
              {
                "id": 142960590,
                "url": "https://finnhub.io/api/news?id=c5926a8a854f428679082b9816725c53cdafe5c734def83695422491bdeefea2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/16/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year yield hovered around 5.1%, gold bounced toward $4,200 and bitcoin traded near $81,300.",
                "category": "company",
                "datetime": 1792153986,
                "headline": "Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today"
              },
              {
                "id": 142928564,
                "url": "https://finnhub.io/api/news?id=eafe019c62ce64669af4574e6e975ab26ea081c2dd6074fd2f03985d0eaf7773",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s upcoming cancer vaccine data, Coca-Cola’s new KFC beverage partnership and Visa’s expanding services business stoked investor interest.",
                "category": "company",
                "datetime": 1792120729,
                "headline": "Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today?"
              },
              {
                "id": 142921387,
                "url": "https://finnhub.io/api/news?id=d354ceae5bd17c60de9d2be01a6d7f7ab88d2948dad79a1837d27e89a76c5d33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the latest market and sector action, highlighting what the sell-off in CoreWeave (CRWV) and chip stocks means for the rest of the market.",
                "category": "company",
                "datetime": 1792093585,
                "headline": "As chip stocks fall, investors are turning elsewhere in the market: Chart of the Day"
              },
              {
                "id": 142921517,
                "url": "https://finnhub.io/api/news?id=8c3da465e9e0bdb90c7940172faecbe1878e4269fe6803587001c2961d490742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral rating.",
                "category": "company",
                "datetime": 1792093362,
                "headline": "MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data"
              },
              {
                "id": 142920417,
                "url": "https://finnhub.io/api/news?id=0fcc6a99bb57e8d09d485a37d2e2d7d64a2221923ab8736bdb870d379724be43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.",
                "category": "company",
                "datetime": 1792083305,
                "headline": "Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher"
              },
              {
                "id": 142919826,
                "url": "https://finnhub.io/api/news?id=5f62ae2ffc34d09948943f0a9e59acd49547181c65388b6c0146533f57da300c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.",
                "category": "company",
                "datetime": 1792082102,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142920873,
                "url": "https://finnhub.io/api/news?id=4d9aa579e79067235c8ba3c8a3f3fa01278e02da1042d19401a1dd2caa942506",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna stock is a \"Hold\" due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Read the full analysis here.",
                "category": "company",
                "datetime": 1792074246,
                "headline": "Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain"
              },
              {
                "id": 142945322,
                "url": "https://finnhub.io/api/news?id=8ed3e6b98969460c0fc7bfbb16db19e96e60d4cb947825faae3b2fcf5d8a1667",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Defensive-Stocks-Puzzle-Utilities-Health.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Concerns about tech companies overspending on AI prompted investors to rotate out of the trade and seek value elsewhere. ",
                "category": "company",
                "datetime": 1792073724,
                "headline": "Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks"
              },
              {
                "id": 142945625,
                "url": "https://finnhub.io/api/news?id=f12791c4c64f65bdc761f41f50cf294e6c7568cd4d68f2aa11b60f5b1cd155f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Marek Poszepczynski spoke with Proactive's Stephen Gunnion about emerging cancer treatments, upcoming clinical trial catalysts and the trust’s fifth consecutive year of benchmark outperformance. Speaking after a therapeutics conference in Boston, Poszepczynski highlighted developments involving Revolution Medicines, AstraZeneca, Summit Therapeutics and Moderna, with a focus on potential advances in pancreatic cancer, lung cancer and melanoma. He discussed the prospects for Revolution Medicines’ pancreatic cancer treatment, AstraZeneca’s AVANZAR trial and upcoming data from Summit Therapeutics that could challenge Merck’s blockbuster KEYTRUDA. Moderna’s melanoma results also featured, with further data expected to help clarify the treatment’s potential. Poszepczynski said IBT prioritises companies addressing significant unmet medical needs, focusing on treatments that could change clinical practice rather than deliver incremental improvements. He also explained how disciplined portfolio management has helped the trust outperform its benchmark for five consecutive years. This includes selling investments when valuations reach target levels and managing exposure to high-risk clinical trial events. Acquisition activity has also contributed to performance, with Poszepczynski saying more than a quarter of the portfolio was acquired by other companies over the previous year. Watch the full interview for his views on the latest oncology developments, upcoming clinical catalysts and the investment strategy behind IBT’s performance. Visit Proactive's YouTube channel for more biotechnology, healthcare and investment interviews. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. #InternationalBiotechnologyTrust #IBT #BiotechInvesting #BiotechStocks #Proactive #MarekPoszepczynski #Biotechnology #HealthcareInvesting #Oncology #CancerResearch #ClinicalTrials #Pharmaceuticals #InvestmentTrusts #PortfolioManagement #BiotechInnovation #RevolutionMedicines #SummitTherapeutics #Moderna #AstraZeneca #Merck #Keytruda #DrugDevelopment #InvestmentPerformance",
                "category": "company",
                "datetime": 1792072066,
                "headline": "IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance"
              },
              {
                "id": 142914091,
                "url": "https://finnhub.io/api/news?id=8050d0fb56e874bfe36f92adcec961a5cef1c04ef7a04d0718b18aa317f99178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.",
                "category": "company",
                "datetime": 1792066848,
                "headline": "Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?"
              },
              {
                "id": 142915781,
                "url": "https://finnhub.io/api/news?id=5325fd16d977cce2122399699832bb035f0ed958bfbb030ac2049e525fd40c10",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.",
                "category": "company",
                "datetime": 1792053069,
                "headline": "Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 142918183,
                "url": "https://finnhub.io/api/news?id=b4cdfa1825a67292882031ef4b584398f3987db1a70ab883b009b373f112f235",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.",
                "category": "company",
                "datetime": 1792049009,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137"
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142885199,
                "url": "https://finnhub.io/api/news?id=8719c4b8e9632570b216f01e32f4bd5f253af404e968afa86404db29c4b76bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791990840,
                "headline": "Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142882995,
                "url": "https://finnhub.io/api/news?id=5bee88da8be6c1a1e20df2f644bb864a5333799ee01c16672580138bd0beea64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791985560,
                "headline": "Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142877597,
                "url": "https://finnhub.io/api/news?id=ee485ffa353f95fe16ec1c801f3480957cdbc1614c6525f24ae2c64f26aed4b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Gabelli Funds Portfolio Manager Justin Bergner and NYSE Senior Market Strategist Michael Reinking break down how the AI boom, rising interest rates, and geopolitical tensions are fundamentally reshaping the stock market.",
                "category": "company",
                "datetime": 1791972000,
                "headline": "What the interest rate danger zone means for your money"
              },
              {
                "id": 142852474,
                "url": "https://finnhub.io/api/news?id=288e96a0f39976996dc6855674ee391f80bb8691dcb257d54e15af7043c4f3ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?",
                "category": "company",
                "datetime": 1791903660,
                "headline": "MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142882290,
                "url": "https://finnhub.io/api/news?id=dad524e982dd6c58bdb1fa3180264aef3534e3fa2d3d927ace66c7ffc4b03f05",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791898511,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142848728,
                "url": "https://finnhub.io/api/news?id=4ff718c0d17dfa447f9637b4c4aecc5e4e89c933ebad91449ca247f2ad041a9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.",
                "category": "company",
                "datetime": 1791895025,
                "headline": "Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142847926,
                "url": "https://finnhub.io/api/news?id=123cdc6d0ab0a2796cf336c8a3776abd50b85fd1ff13a6aa674423cb8464ac24",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1791894901,
                "headline": "Tuesday's pre-market session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 142847594,
                "url": "https://finnhub.io/api/news?id=2f0115d035c32c47a669478e2f0a61b88dc4f37e834405d995eea48d7da51293",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a. ET on Friday, November 6, 2026 to report its third quarter 2026 financial results, and provide a corporate update.",
                "category": "company",
                "datetime": 1791889200,
                "headline": "Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026"
              },
              {
                "id": 142848040,
                "url": "https://finnhub.io/api/news?id=9e6dafae442f96026a265b8b3c3d2e060891d304bc6b6f2278911b4ff4a22654",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253962329/image_2253962329.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "U.S. equity markets were mixed this week, with broader gains across value, defensive, and cyclical sectors offset by weakness in technology and the NASDAQ 100.",
                "category": "company",
                "datetime": 1791882900,
                "headline": "ValuEngine Weekly Commentary With Strategy Notes"
              },
              {
                "id": 142841955,
                "url": "https://finnhub.io/api/news?id=f26ca8df2edfe36d48bbd35dad4514614cc7a7b79061094506f25b8be0158498",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Is bigger always better? Not necessarily.",
                "category": "company",
                "datetime": 1791882240,
                "headline": "Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?"
              },
              {
                "id": 142844367,
                "url": "https://finnhub.io/api/news?id=66560ff9f3f37bf54fdf7009dcfee55437ea1d91b6ce9ebd018012482868e7b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242072348/image_2242072348.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into tech.",
                "category": "company",
                "datetime": 1791873000,
                "headline": "S&P Hits All-Time Highs, AI Trade Does All The Work"
              },
              {
                "id": 142832198,
                "url": "https://finnhub.io/api/news?id=d3ea8e257978166d5e746743c7288a47771d0314699386d25faf85b0c5e2d4a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.",
                "category": "company",
                "datetime": 1791858206,
                "headline": "Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines"
              },
              {
                "id": 142824554,
                "url": "https://finnhub.io/api/news?id=44630c809357e2f07010f9d4cdb465c71d19dd1f54e2d65b83653012ff28c8ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales have fallen for three consecutive years, and nearly all of that revenue still comes from COVID vaccines. This divergence suggests investors are placing heavy bets on a product Moderna does not sell yet. So what is Moderna getting ready to sell, and how far along is it.",
                "category": "company",
                "datetime": 1791838902,
                "headline": "Where Could Moderna's Next Growth Come From?"
              },
              {
                "id": 142824630,
                "url": "https://finnhub.io/api/news?id=43df23e601f4825f694952c4d6c8d28928860c31593421aec5e57e82831752db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791838203,
                "headline": "Here's Why Moderna (MRNA) Fell More Than Broader Market"
              },
              {
                "id": 142823403,
                "url": "https://finnhub.io/api/news?id=7d346a60f670e8f9ddc8279296e8c4fd9cae67d242e655a952cce9bcd63808f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791831901,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 142822735,
                "url": "https://finnhub.io/api/news?id=0d838ad684b027caa0cf0df8d0c80c8fb4001955df05b1ec8d509ebe13fd36bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100",
                "category": "company",
                "datetime": 1791826428,
                "headline": "Moderna stock surges more than 600% in 2026"
              },
              {
                "id": 142822732,
                "url": "https://finnhub.io/api/news?id=dc400d678e5afb7aec6e1693488e62f662c93be576b78ff8f0f53e7d71d9c2e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program with Moderna, a development now linked to a planned public private cancer vaccine partnership. Recent headlines around Merck’s mRNA cancer vaccine work sit alongside a busy few weeks that included the SPR2015 KRAS licensing deal, new adult access to CAPVAXIVE in Ontario, and an early trial start using Cyprumed’s oral delivery technology. Against that backdrop, Merck’s...",
                "category": "company",
                "datetime": 1791824861,
                "headline": "Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results"
              },
              {
                "id": 142821651,
                "url": "https://finnhub.io/api/news?id=c9d831442b9c1045fb85a7b44fe95907e600ec62df59c720cb57891bfd1f67cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.",
                "category": "company",
                "datetime": 1791816360,
                "headline": "Tempus AI Expands Strategic Collaborations to Drive Future Growth"
              },
              {
                "id": 142821797,
                "url": "https://finnhub.io/api/news?id=101e25e7c4ca9a920679bb28ba1c583059215c31ea63222d3ce3d0ee418bae7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and human control concerns dominated recent industry discussions, the quarterly letter highlights the massive, untapped potential of deploying existing AI capacity into industrial applications. The letter […]",
                "category": "company",
                "datetime": 1791815227,
                "headline": "Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally"
              },
              {
                "id": 142821652,
                "url": "https://finnhub.io/api/news?id=1d256551eb6855fe5613b6462f6afe2fd779b9bd9aba8f8ba545910b1137d5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.",
                "category": "company",
                "datetime": 1791814320,
                "headline": "Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines"
              },
              {
                "id": 142819797,
                "url": "https://finnhub.io/api/news?id=da93845afd3b4bf11846e0e74f24619b7acfd2d2516cd5d52ffd7d3f8a522f5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocks were little changed on Monday ahead of a big earnings week.",
                "category": "company",
                "datetime": 1791812522,
                "headline": "Tech slumps as oil prices rise, focus turns to earnings season kickoff: AlphaCheck"
              },
              {
                "id": 142822445,
                "url": "https://finnhub.io/api/news?id=6a9b5a81416b333cfcb565f96c7c45b8def604f362c6a7ebf08f6f14592ed8fb",
                "image": "https://image.cnbcfm.com/api/v1/image/108398008-17918081451791808141-48951856214-1080pnbcnews.jpg?v=1791808144&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the public-private push to accelerate cancer vaccine development, his thoughts on the current flu season, AI integration in hospitals, and more.",
                "category": "company",
                "datetime": 1791795999,
                "headline": "Dr. Scott Gottlieb on push to fast-track cancer vaccines, flu season and AI integration in hospitals"
              },
              {
                "id": 142816306,
                "url": "https://finnhub.io/api/news?id=330fbaf9b5174030e308e65d940a51f4bcbe56e9b042ae7e7722b12c2bf35252",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Forget the \"Magnificent Seven\" in favor of the \"Tremendous Three\"?",
                "category": "company",
                "datetime": 1791795840,
                "headline": "These 3 Stocks Are Crushing the \"Magnificent Seven\" This Year -- Are They Still Buys?"
              },
              {
                "id": 142819667,
                "url": "https://finnhub.io/api/news?id=7a635c49ac41617cd1ad673f2d4a6c50cf6070ab530de9320081ef1197b68a98",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'",
                "category": "company",
                "datetime": 1791795613,
                "headline": "Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’"
              },
              {
                "id": 142819668,
                "url": "https://finnhub.io/api/news?id=99434cce829fc22f2fec5d8aa6a330985e5f0d6f9f7ce48d33775dc15d6b2ee2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Stephen-King-at-New-York-Comic-Con.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.",
                "category": "company",
                "datetime": 1791781934,
                "headline": "Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'"
              },
              {
                "id": 142811129,
                "url": "https://finnhub.io/api/news?id=aa4e6af2649f3f9eeb6605ff7b67664cda878a49a5317f2d94fbdf632020f8e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The rallies highlighted growth opportunities across biotechnology, health insurance and optical technology.",
                "category": "company",
                "datetime": 1791774188,
                "headline": "Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week?"
              },
              {
                "id": 142806504,
                "url": "https://finnhub.io/api/news?id=f878fb480560c54695b440396708c4874208ab84ae6a77ef66a66f1a2b97bd9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would return as Chief Operating Officer to oversee scaling for its personalized cancer vaccine candidate, intismeran autogene, following positive Phase 3 melanoma results. This combination of index inclusion and operational leadership focused on oncology suggests Moderna is entering a new phase of portfolio diversification beyond its initial COVID-19 vaccine focus. We’ll...",
                "category": "company",
                "datetime": 1791727967,
                "headline": "Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And Nasdaq-100 Return Has The Bull Case Changed?"
              },
              {
                "id": 142805345,
                "url": "https://finnhub.io/api/news?id=e83de194b1b87aaf442967a3482ff32a937dde1a527eb9cc5476c72769b7f1b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has surged back into the spotlight after a powerful share price run, which puts a fresh focus on whether the current US$225.00 level can be supported by the sales the business is generating. After that kind of move, the key issue for anyone looking at the stock is how its revenue base lines up with the price now being asked in the market. The stock has delivered a very large 1 year return of about 7x, which raises the stakes on whether recent performance is in line with what its...",
                "category": "company",
                "datetime": 1791720824,
                "headline": "Moderna (MRNA) Stock Looks Expensive Following Its 7x One Year Run"
              },
              {
                "id": 142805020,
                "url": "https://finnhub.io/api/news?id=e93b52c82892cafc250ab1f7952c55d1c3fc90c2321615b065e2ab862300d30d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s updated modelling now points to a slightly higher fair value estimate, with the figure moving from US$119.56 to US$122.67 per share. That shift lines up with recent analyst commentary that treats the intismeran cancer vaccine program as an important driver, even as some firms argue that higher price targets are hard to square with questions on oncology revenue assumptions. Read on to see how this evolving narrative around Moderna, its pipeline, and valuation inputs could shape what...",
                "category": "company",
                "datetime": 1791716980,
                "headline": "Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions"
              },
              {
                "id": 142795870,
                "url": "https://finnhub.io/api/news?id=cfea27c2bcc3854662f95ec52871962c40ba9898021bf05594b2e427776a803f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "After a few years of stagnation, this stock is soaring.",
                "category": "company",
                "datetime": 1791671700,
                "headline": "Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?"
              },
              {
                "id": 142795832,
                "url": "https://finnhub.io/api/news?id=4324a077ff4a72a38f2d5f3780564f0c42d186f4763ee7da222becfe6f97e70b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is up 663% in 2026, beating AI names for the S&P 500 lead. Full cancer vaccine data arrives October 24.",
                "category": "company",
                "datetime": 1791671034,
                "headline": "A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year"
              },
              {
                "id": 142792628,
                "url": "https://finnhub.io/api/news?id=ff3b3be067a4c287f88208fb12b78c29d20a59d27d74e110fe1720f8e2fbea04",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1791630102,
                "headline": "The 1-Minute Market Report October 10, 2026"
              },
              {
                "id": 142792567,
                "url": "https://finnhub.io/api/news?id=11a786498782afaccf0262d5570d06ee18a18ddd114c981cf9f7594cc7351290",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Preview next week’s market-moving events—CPI, retail sales, Fed talk, and big bank earnings (JPM, GS, C, MS).",
                "category": "company",
                "datetime": 1791630000,
                "headline": "Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In Focus"
              },
              {
                "id": 142769670,
                "url": "https://finnhub.io/api/news?id=9d3295f3bb1adffe88e68237811e5227ae5d48cec72684a1c0f63434b017580a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.",
                "category": "company",
                "datetime": 1791590964,
                "headline": "BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push"
              },
              {
                "id": 142771076,
                "url": "https://finnhub.io/api/news?id=f56bd64c9b264ca01fd46e7475092dc34ffa8ab476200e9a0d2c7a0ddb5ec296",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech could play a significant role in a national effort to combat cancer.",
                "category": "company",
                "datetime": 1791590851,
                "headline": "Why Moderna Stock Surged Today"
              },
              {
                "id": 142767230,
                "url": "https://finnhub.io/api/news?id=32888a724310a8ebb739390192df3753f6140611aa23b6d020d6eeeaf5dfde0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.",
                "category": "company",
                "datetime": 1791577388,
                "headline": "MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push"
              },
              {
                "id": 142767234,
                "url": "https://finnhub.io/api/news?id=d7d5f0fd22730d92951f2014ccb62427ee49edb1d22e29743ec0b95307cbbb76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "US equity indexes ended higher Friday after a broad-based rally and strong gains in mega-cap technol",
                "category": "company",
                "datetime": 1791577320,
                "headline": "US Equity Markets End Higher Amid Broad Rally, Strong Mega-Cap Gains"
              },
              {
                "id": 142767070,
                "url": "https://finnhub.io/api/news?id=743b0382a723cbdc32d43787735790af20fd09acef17e366f8d38a2214800229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Have Moderna’s shares risen too much, too fast?",
                "category": "company",
                "datetime": 1791577202,
                "headline": "This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street"
              },
              {
                "id": 142767233,
                "url": "https://finnhub.io/api/news?id=15826fa17b57f86c4b629b7026146c99a3f083786b9f2f3f995c106283882fad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Why Everest Medicines Stock Is Back On Investors’ Radar Everest Medicines (SEHK:1952) just added two experienced mRNA cancer vaccine scientists, Lakshmi Srinivasan, PhD, and Brandon Coder, PhD, to help advance its AI+mRNA platform and upcoming clinical programs. Those hires come at a time when Everest Medicines’ share price has been volatile, with a 90 day share price return of 7.64%, a year to date share price return down 21.9%, and a 1 year total shareholder return down 44.36%. This points...",
                "category": "company",
                "datetime": 1791576753,
                "headline": "Everest Medicines (SEHK:1952) Gains Fresh MRNA Firepower As Undervalued View Holds"
              },
              {
                "id": 142767148,
                "url": "https://finnhub.io/api/news?id=317e2a4ac9bd7cae9e89e143d2b9dc3ccea939aa2979a3895e46147f424bc6e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State S",
                "category": "company",
                "datetime": 1791575829,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 142773141,
                "url": "https://finnhub.io/api/news?id=d751c85017e1302e416e6bb9ec54f81278330dd63ea7b9a76ca4adb0a9fcdc1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.",
                "category": "company",
                "datetime": 1791573430,
                "headline": "Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative"
              },
              {
                "id": 142765953,
                "url": "https://finnhub.io/api/news?id=fa69fc8000049deee244f45ce89b56b001c6c1c2df31ee60616bdbf8d43bd682",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791572701,
                "headline": "Discover which S&P500 stocks are making waves on Friday."
              },
              {
                "id": 142765621,
                "url": "https://finnhub.io/api/news?id=1fa9f1c674574e0933237001e1e66d77711e406a331cd57995c1136d4894f80d",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1791569102,
                "headline": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session."
              },
              {
                "id": 142765422,
                "url": "https://finnhub.io/api/news?id=631b204a897242e9067909ca94cf040449d481cd1c86236d331f3a110e4b093d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%. Also rallying, Moderna (NASDAQ:MRNA) shares are at $219.30, up 11%, a double-digit gain that still trails Novavax stock. Meanwhile, Merck (NYSE:MRK) shares […]",
                "category": "company",
                "datetime": 1791568782,
                "headline": "Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies"
              },
              {
                "id": 142765272,
                "url": "https://finnhub.io/api/news?id=bbe1f2ebcbdec19b2d3d7a9225e75ca95b9ff0d43fd56d4c93f423c792c747fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street",
                "category": "company",
                "datetime": 1791568225,
                "headline": "Sector Update: Healthcare Stocks Gain Friday Afternoon"
              },
              {
                "id": 142767147,
                "url": "https://finnhub.io/api/news?id=26ef6d462271e20560d857d34bb2b7d1b91d3c0bed8b86406e36dfb355f69c39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock hits 4-year high on planned national cancer vaccine effort"
              },
              {
                "id": 142765274,
                "url": "https://finnhub.io/api/news?id=b511a432760eaf585dcbace8a10945d149a4dcfeb9e406c5b84325a24f8870a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock jumps on planned national cancer vaccine effort"
              },
              {
                "id": 142764187,
                "url": "https://finnhub.io/api/news?id=548ea96d85965d4231150ac723e0b762e14ae359a530daca3345e608b530e44e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.",
                "category": "company",
                "datetime": 1791560934,
                "headline": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up"
              },
              {
                "id": 142791500,
                "url": "https://finnhub.io/api/news?id=b99251c849f7a1c45efa6bd9815de84bb2e70dac7f936818418f006549e03647",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here's what you should know.",
                "category": "company",
                "datetime": 1791559092,
                "headline": "Moderna Stock Hits New 52-Week High: What's Happening?"
              },
              {
                "id": 142791501,
                "url": "https://finnhub.io/api/news?id=10b61961f7807912d26796789297a2d0c536581d343ea6718415855d204068b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.",
                "category": "company",
                "datetime": 1791558672,
                "headline": "A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally"
              },
              {
                "id": 142791211,
                "url": "https://finnhub.io/api/news?id=8515c8cafa622c1ba55b6a4727cf33da0134590c035e2163865fea16ff57ffd7",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1791552910,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142791247,
                "url": "https://finnhub.io/api/news?id=6d6a7f613588e29781ea47aa1622e652afe48f306894f204f475dfe565f02ff3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Los-Angeles--California--May-20--2024-T-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The Nasdaq 100 recovers from Thursday's OpenAI-driven selloff while T-Mobile sinks 12% on SpaceX's spectrum deal and the 10-year yield holds near 5.26%.",
                "category": "company",
                "datetime": 1791552427,
                "headline": "Stock Market Today: Nasdaq 100 Rebounds From OpenAI Scare, T-Mobile Tumbles 12%"
              },
              {
                "id": 142763629,
                "url": "https://finnhub.io/api/news?id=878e8a8319515c43d93f8a05679617ac33f23f6ab80e54cd4feeb14c139564e5",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html",
                "category": "company",
                "datetime": 1791543602,
                "headline": "Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times"
              },
              {
                "id": 142763365,
                "url": "https://finnhub.io/api/news?id=e8a33e2e34eb5ad9a85389b5450190ce06b03de47ad677f6b29818663259167f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Stuttgart--Germany---07-28-2023-Person-H.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.",
                "category": "company",
                "datetime": 1791543065,
                "headline": "Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 142744648,
                "url": "https://finnhub.io/api/news?id=bc8e816542216a9dccee1141b325eaf7c674aeb28d49af3cffe9b098f92f600c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Everest Medicines (HKEX 1952.HK, \"Everest\", or the \"Company\"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The appointments further strengthen the Company's global R&D capabilities in mRNA therapeutics, an",
                "category": "company",
                "datetime": 1791512100,
                "headline": "Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development"
              },
              {
                "id": 142739970,
                "url": "https://finnhub.io/api/news?id=17a72026cbe6ce0c10a7144d1a875f5666cdcd68f08d4a852ca83ee3857ac279",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery. Moderna left that index in December 2024, and what has changed since is the market value […]",
                "category": "company",
                "datetime": 1791510286,
                "headline": "Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?"
              },
              {
                "id": 142731194,
                "url": "https://finnhub.io/api/news?id=faf7a0129a4c5dc62aa1fd9b26271828adef20c668387f3e65a475e6c3c97390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BOSTON, October 08, 2026--eClinical Solutions LLC, a global provider of digital clinical software and services, will convene global technology and biopharma leaders October 12-14 for its eighth annual client and partner conference, ENGAGE 2026. The company will host over 250 attendees at W Philadelphia, including representatives from over 75 life science organizations such as GSK, Moderna, Bayer, Takeda, Daiichi-Sankyo, Vertex, Eisai, ICON, and industry partner corporate sponsors including PwC a",
                "category": "company",
                "datetime": 1791481260,
                "headline": "eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026"
              },
              {
                "id": 142727251,
                "url": "https://finnhub.io/api/news?id=f7b2dc60e7944c418a54200a105d62bafcdc6bf6b92eaf8327925bd73a4ef4cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.",
                "category": "company",
                "datetime": 1791459720,
                "headline": "Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?"
              },
              {
                "id": 142725284,
                "url": "https://finnhub.io/api/news?id=27135e9e07b38f712fa76d28aca7aafd38bbc9d427ad47bc19efe577d51ea1a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?",
                "category": "company",
                "datetime": 1791459058,
                "headline": "3 Stocks That Have More Than Doubled the S&P 500’s Return This Year"
              },
              {
                "id": 142719466,
                "url": "https://finnhub.io/api/news?id=87d19cb278158784eb0178fd4b05454844fe1c754b737dbd092cb5218c672b9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Companies In The Article are:STZ,PENG,SPCX,MRNA",
                "category": "company",
                "datetime": 1791447780,
                "headline": "Company News for Oct 8, 2026"
              },
              {
                "id": 142719471,
                "url": "https://finnhub.io/api/news?id=11e47815ee394b98e4d0ccfee74bf1eb0154b87e02373ec0c6c1996eec020d9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Thursday, Oct, 8 2026 US Market stock futures are essentially flat, with E-mini S&P 500 contracts edging up only fractionally as investors weigh strong demand for imported goods against early signs of improving sentiment. The US trade deficit widened to a 17 month high of $105.6b in August, with imports hitting a record $420.8b. That points to solid consumer and business appetite, yet it can also add to price pressures through higher costs on...",
                "category": "company",
                "datetime": 1791447088,
                "headline": "US Stock Market Today: S&P 500 Futures Hold Flat As Trade Deficit Worries Return"
              },
              {
                "id": 142727055,
                "url": "https://finnhub.io/api/news?id=58bccab68fc54cae0b3b7fee41a3bfdbe01117018ca16d59a9a039d148c60a9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://www.bloomberg.com/news/articles/2026-10-08/russia-denies-report-of-second-case-of-illness-in-siberia",
                "category": "company",
                "datetime": 1791439197,
                "headline": "'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg"
              },
              {
                "id": 142708288,
                "url": "https://finnhub.io/api/news?id=a86cc9f70738734096f7a1ec3ceb9af0cdd31713eec61c58ecf1764de5d90caa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.",
                "category": "company",
                "datetime": 1791426542,
                "headline": "Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142729845,
                "url": "https://finnhub.io/api/news?id=c014997ea957db0fc1fb6fa694849438778cb31eac31201357a3ff84d06878f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tempus, a medical testing and healthcare tech company, has partnered with industry giants like Merck and Moderna to revolutionize healthcare. Founder and chief executive Eric Lefkofsky discusses these partnerships, Tempus's financial strategy and the success and failures of AI in healthcare.",
                "category": "company",
                "datetime": 1791407580,
                "headline": "Tempus CEO on How AI Can Save Healthcare"
              },
              {
                "id": 142700318,
                "url": "https://finnhub.io/api/news?id=bbc077f2bed73509ccbbbdf77e170ed9eb13fbb99ec147f5b11a941fbe75838b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The healthcare sector stood out as one of the few bright spots in Wednesday’s trading.",
                "category": "company",
                "datetime": 1791404398,
                "headline": "Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets"
              },
              {
                "id": 142699051,
                "url": "https://finnhub.io/api/news?id=4969bb37167e933cfd7558289b21f83b2434a2d4a02d1d83b878f78ff6fb8b48",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1791399901,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142699201,
                "url": "https://finnhub.io/api/news?id=8199d09c1f9f7471d9cef46b9b5a0f5819c04e5dd45efce183f4205620b9542b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231926077/image_2231926077.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. Read more here.",
                "category": "company",
                "datetime": 1791388080,
                "headline": "Cedar Grove Capital Q3 2026 Portfolio Update"
              },
              {
                "id": 142697301,
                "url": "https://finnhub.io/api/news?id=42cb2a379378ef1912ba87fb86ca2af6da717509d428b5bc364ccfe506c9f6ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech’s VP of Drug Product Operations Michelle Rodriguez on how it works with CDMOs.",
                "category": "company",
                "datetime": 1791384194,
                "headline": "CPHI 2026: Moderna builds on its COVID-era manufacturing lessons"
              },
              {
                "id": 142727689,
                "url": "https://finnhub.io/api/news?id=111a5acaac46f167d1961c88b8fc1c3249af2292e699a5d3873804e67dbd074c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Tempus-AI-Logo-On-Mobile-Phone.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.",
                "category": "company",
                "datetime": 1791380692,
                "headline": "Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure"
              },
              {
                "id": 142694830,
                "url": "https://finnhub.io/api/news?id=a910c3cf1307093aa71a865be7653c98d311d7479d788b9de6f7506bfabb510d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CHICAGO, October 07, 2026--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know",
                "category": "company",
                "datetime": 1791376200,
                "headline": "Tempus Announces Multi-Year Collaboration with Moderna and Merck"
              },
              {
                "id": 142727690,
                "url": "https://finnhub.io/api/news?id=9220abdf46470e3372153beb5281c74be58c922cc735633d91f81ebe26b79d9d",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $89 to $95.",
                "category": "company",
                "datetime": 1791370292,
                "headline": "Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $95"
              },
              {
                "id": 142690911,
                "url": "https://finnhub.io/api/news?id=254278c2e3b8fe9ad6af44a36f86ff9808090d83ad4dec8e818133c9b00eb395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesday after both companies rose in the previous session following reports of a suspected pneumonic plague case in Russia. Novavax shares fell 11% after gaining 20% on Tuesday, while Moderna declined 6% following a 7% increase in the prior session.",
                "category": "company",
                "datetime": 1791368781,
                "headline": "Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility"
              },
              {
                "id": 142686591,
                "url": "https://finnhub.io/api/news?id=657f9761d2dfdc2106424e37fe6311032c1767ee4783a979d1d50a82e4d87a39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791366798,
                "headline": "Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys"
              },
              {
                "id": 139932206,
                "url": "https://finnhub.io/api/news?id=c42aff9b13dbfcf1a32071436d2e13e0b0dd8cc7e6a73149614855d15df8c78d",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1791362110,
                "headline": "The FDA Has Accepted And Granted Priority Review To The Biologics License Application For Daiichi Sankyo/Merck's Patritumab Deruxtecan For Pretreated Locally Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer"
              },
              {
                "id": 142682425,
                "url": "https://finnhub.io/api/news?id=64c66b4613237deb437402981f92ecfd5c925207ce42fafb2074d1c2858d71e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791359399,
                "headline": "Dow Jones Future Fall After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys, But These Stocks Slammed"
              },
              {
                "id": 142683943,
                "url": "https://finnhub.io/api/news?id=24e8f76eda4c60156468bff0fa39f76a8f7dc3ca177fe672d80d92754c507ec8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) appointed former executive Juan Andres as its new Chief Operating Officer in a newly created role, giving investors additional information to weigh against a sharp recent move in the stock. Recent trading has been choppy for Moderna, with the share price down 7.8% over the past day and week, yet still posting a 28.8% 30 day share price return and a very large year to date gain, while the 1 year total shareholder return also remains very high despite a weaker 5 year record...",
                "category": "company",
                "datetime": 1791357415,
                "headline": "Moderna (MRNA) Could Be 57% Above Fair Value On New COO Appointment"
              },
              {
                "id": 142668537,
                "url": "https://finnhub.io/api/news?id=721d6d5edcfaf9ef44effdde15fa410c28c6a281fe4be4edd2c0f998f6ab351a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791322696,
                "headline": "Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead Buys, But These Stocks Tumble"
              },
              {
                "id": 142669648,
                "url": "https://finnhub.io/api/news?id=180202710dc273203341b97a088d7077330217059d53f32c5a075393bde007eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The death of a Russian lab technician triggers fears of a pneumonic plague outbreak, even as health officials downplay the risk.",
                "category": "company",
                "datetime": 1791320640,
                "headline": "Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare."
              },
              {
                "id": 142668643,
                "url": "https://finnhub.io/api/news?id=a530aab6542cb6f6f2fa5615475ba3036ce5d64291da8a522a1807f43791fdb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "These stocks have all soared more than 350% this year.",
                "category": "company",
                "datetime": 1791318002,
                "headline": "Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?"
              },
              {
                "id": 142667425,
                "url": "https://finnhub.io/api/news?id=799cd2ca19736d45c52db9faa5f9160ef65f2f81c348e1bda7366c44deea05c5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the top performers within the S&P500 index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791313501,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142667782,
                "url": "https://finnhub.io/api/news?id=5be42c579586235957ebe3854c6f16f5170e52eeb4ec0992ee781fdb6d35f2b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real, and so is the risk of giving it all back.",
                "category": "company",
                "datetime": 1791313383,
                "headline": "Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?"
              },
              {
                "id": 142666223,
                "url": "https://finnhub.io/api/news?id=77d86f15549f5f68cb794b92dd883f9ce67028af48767f3a173cdb7c589f7e8d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.",
                "category": "company",
                "datetime": 1791304502,
                "headline": "Which S&P500 stocks are moving on Tuesday?"
              },
              {
                "id": 142665693,
                "url": "https://finnhub.io/api/news?id=6269f2bea8baec5db48921fc0113fe6e796197b632a4784659dc96f9483af9ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Novavax stock slid on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a \"low\" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last week.",
                "category": "company",
                "datetime": 1791302343,
                "headline": "Novavax, Moderna stocks fall after WHO calls plague risk 'low'"
              },
              {
                "id": 142665591,
                "url": "https://finnhub.io/api/news?id=4fe7eff21e7fc3ab280e5978693cc4f9850e9ea6400a8bab1ab7d9c4e8677d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.",
                "category": "company",
                "datetime": 1791301145,
                "headline": "Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers"
              },
              {
                "id": 142664476,
                "url": "https://finnhub.io/api/news?id=293a1e63d2d9f8d35ccf43537079ef2352e40d44a0deea52ecbe4d188ab55d23",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1791297302,
                "headline": "Tuesday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 142665590,
                "url": "https://finnhub.io/api/news?id=b8c24771ec9f2acfa0c2c2695e7d6df91fc9d0d11a2219c92c917dfea329fe3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.",
                "category": "company",
                "datetime": 1791297120,
                "headline": "Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?"
              },
              {
                "id": 142668859,
                "url": "https://finnhub.io/api/news?id=e0e128374aa47ad5a23e2076967c3d01abfff200ac3a3843cc6d371cbdfa9307",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The 8:30 Hosts Julie Hyman, Pras Subramanian, and Jake Conley outline trending stories to watch on Tuesday: AMD (AMD) CEO Lisa Su's recent comments, Paramount's (PSKY) deal with Warner Bros. (WBD) finally closing, Moderna (MRNA) and other pharmaceutical stocks climbing, and Banco Bradesco (BBD) stock jumping on Brazilian election polls.",
                "category": "company",
                "datetime": 1791297103,
                "headline": "Paramount–Warner Bros. deal finally closes: Stocks to watch on Tuesday"
              },
              {
                "id": 142663741,
                "url": "https://finnhub.io/api/news?id=631504fc4ba1b24349758aad4495c3d34a2c08ba4b66f10e9572c1680c84e8bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address. Novavax stock trades at $12.32, down 2% in morning […]",
                "category": "company",
                "datetime": 1791294963,
                "headline": "Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher"
              },
              {
                "id": 142663017,
                "url": "https://finnhub.io/api/news?id=add7b011130caf548ecd5881d8dd0693a9a2406ba8ba6069c4b9fc9aba32dd92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "One group of shareholders walks away with cash at closing. The other inherits a renamed company on a new exchange carrying roughly $80 billion in debt, and the settlement terms make the usual escape routes unavailable.",
                "category": "company",
                "datetime": 1791292245,
                "headline": "The $110 Billion Paramount-Warner Merger Closes Today. What Shareholders Need to Know"
              },
              {
                "id": 142658761,
                "url": "https://finnhub.io/api/news?id=f7f9ba42bf795a8ba5ac93ca3deca7c3b67ceeb97d78b96746a91e1219253b98",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1151934014/image_1151934014.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "US equity markets were mixed this week, with gains in tech-related areas offset by weakness across several broader market and defensive sectors. Read more here...",
                "category": "company",
                "datetime": 1791267600,
                "headline": "ValuEngine Weekly Commentary: YTD And Q3 Performance Analysis, Strategy Notes"
              },
              {
                "id": 142646063,
                "url": "https://finnhub.io/api/news?id=52f9d12bcf8e9ee5110951452e48b2ceb8d3f530e8559745f627fbfa5356b6ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.",
                "category": "company",
                "datetime": 1791257642,
                "headline": "NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'"
              },
              {
                "id": 142662717,
                "url": "https://finnhub.io/api/news?id=0af991e44b8c081ec4bcc3537f414b1df1de5d750dfde4af55ad85a15eb03f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Combination-Products-Face-Scrutiny.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Vaccine stocks are trending on Tuesday.\n\n\n\nShares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday.\n\n\n\nModerna rose 0.17% to",
                "category": "company",
                "datetime": 1791246461,
                "headline": "Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety"
              },
              {
                "id": 142639861,
                "url": "https://finnhub.io/api/news?id=8c936846d13101d763354103e18ec0b7a6e723c479867cfd117e1ba165308aa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.",
                "category": "company",
                "datetime": 1791243744,
                "headline": "NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test"
              },
              {
                "id": 142638487,
                "url": "https://finnhub.io/api/news?id=85fbe6e259994956d206666ce9bd76965db090724695c13359d2045247dc66f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Nasdaq said on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.",
                "category": "company",
                "datetime": 1791228622,
                "headline": "MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns"
              },
              {
                "id": 142638488,
                "url": "https://finnhub.io/api/news?id=b912328faf2b062f4a6208a16967cb22fa7e13d4e2d406d3f1a441f06bfdc313",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?",
                "category": "company",
                "datetime": 1791226022,
                "headline": "Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips"
              },
              {
                "id": 142663889,
                "url": "https://finnhub.io/api/news?id=71fba566269c86e1a224393950391e50a124a91be8fa59983e299ea8b39346e6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/Novavax-Vaccine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.",
                "category": "company",
                "datetime": 1791217941,
                "headline": "Novavax Shorts on Edge as Russia Plague Fears Spread"
              },
              {
                "id": 142662624,
                "url": "https://finnhub.io/api/news?id=dad5fb9983d775cad72c5c2338c949078af0797bb8002c1c8c00ef248e80b39b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791207317,
                "headline": "4 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142631457,
                "url": "https://finnhub.io/api/news?id=ed5145757657485e6e153aa92f1bc00f4fa95475ea53f6450b5d99be3f63fbbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
                "category": "company",
                "datetime": 1791187374,
                "headline": "1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds"
              },
              {
                "id": 142630549,
                "url": "https://finnhub.io/api/news?id=7d9e5e396c8898c7050f63983a8921f960929cb810ab5c0bf558e790bc1a21bc",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_8_5e37f1ec07.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wall Street closed Friday higher after September payrolls came in far below forecasts, cutting the odds of an October rate hike. Nvidia hit a record intraday high, onsemi sweetened its Synaptics deal, storage names slumped and Tesla beat on deliveries.",
                "category": "company",
                "datetime": 1791185268,
                "headline": "A Soft Jobs Report Takes the Heat Off Rates, and Nvidia Closes In on $6 Trillion"
              },
              {
                "id": 142637894,
                "url": "https://finnhub.io/api/news?id=a3323c28ebcc1096a98e4d09641ec0374eb9052ddfbc5ca60c98377669db5a8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Grail’s testing mechanism, dubbed the Galleri, can test for about 50 different cancers from a single blood draw.",
                "category": "company",
                "datetime": 1791172860,
                "headline": "Grail Jumps as Cancer Test Nears Market"
              },
              {
                "id": 142628177,
                "url": "https://finnhub.io/api/news?id=5e559ccc13458107f69a755a0fa898e408a9fd80fe5863d30ee438f401301bbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) ranked as the second top-performing stock in the US market in the third quarter of the year, with the surge primarily driven by rosy growth prospects from its combined therapy candidate for treating the most common type of skin cancer. The vaccine maker—which is set to join the Nasdaq 100 index on […]",
                "category": "company",
                "datetime": 1791169645,
                "headline": "Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?"
              },
              {
                "id": 142626227,
                "url": "https://finnhub.io/api/news?id=0dec8256cd2dbb4ab587c8a73188cde8a2d31a2ec664f70603994d2a0f9ce6fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Mentioning how the FDA advisory panel backed its Galleri multi-cancer early detection test, a caller asked for Jim Cramer’s opinion on GRAIL, Inc. (NASDAQ:GRAL) during the lightning round of the September 30 episode of Mad Money. He replied: You know, I’ve been waiting for that. I’ve been waiting for that approval. And I said, “If […]",
                "category": "company",
                "datetime": 1791156006,
                "headline": "Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)"
              },
              {
                "id": 142616490,
                "url": "https://finnhub.io/api/news?id=d9c2344d2d2cd7c0bfb9fbfb23955a03d2c54ee9c0b0f3d9caf32c350c4a7380",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysMerck stock is up 61% over the past year to $144 at the Oct 2 close, with the sharpest leg coming Aug 19 on the Phase 3 INTerpath-001 melanoma win. Scotiabank’s Sept 29 target hike to $180 from $155 sits 25% above the close.",
                "category": "company",
                "datetime": 1791052306,
                "headline": "Merck Stock Is Up 61% in a Year. Is There Room Left to Run?"
              },
              {
                "id": 142600201,
                "url": "https://finnhub.io/api/news?id=ad55939cdb4eaa81677d2b0c9d6df027c03f898b180fb8c90f7a228a85731309",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2295108677/image_2295108677.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Technology was the place to be among September’s biggest S&P 500 winners, accounting for 13 of the month’s 20 best-performing stocks.",
                "category": "company",
                "datetime": 1790987400,
                "headline": "September's Leaders And Laggards"
              },
              {
                "id": 142594550,
                "url": "https://finnhub.io/api/news?id=db9c2d224e1b2ac38f8b6a998fbae62c7c9419e732fdf7ea6dbe01e8ff19cb9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) appointed Juan Andres as its first Chief Operating Officer as it reshapes its leadership structure. The new COO role focuses on scaling manufacturing for Moderna's personalized cancer vaccine and wider oncology pipeline. Andres returns to Moderna with prior experience overseeing global manufacturing operations at the messenger RNA specialist. The creation of a COO role for Juan Andres only captures part of what is changing inside Moderna right now. Take a look at 1...",
                "category": "company",
                "datetime": 1790978758,
                "headline": "Why Is Moderna (MRNA) Bringing Back A Manufacturing Leader As First COO?"
              },
              {
                "id": 142590775,
                "url": "https://finnhub.io/api/news?id=2aa308b7db9179e6d53e64a0e58f802e9617bfd9558a1cfabad41c0a05e34231",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Nvidia stock is on pace to close at a record high.",
                "category": "company",
                "datetime": 1790950140,
                "headline": "Nvidia, Tesla, Seagate, ON Semi, Strategy, HPE, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142587637,
                "url": "https://finnhub.io/api/news?id=9248aa78a0af2da9f0912cef3c87c196e2d8f32066b75db33516976170895605",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Nike slumps after the retailer misses analysts’ first-quarter earnings target and issues downbeat fiscal-year guidance.",
                "category": "company",
                "datetime": 1790940900,
                "headline": "ON Semi, Synaptics, Nike, Strategy, Moderna, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142587175,
                "url": "https://finnhub.io/api/news?id=f07b6b510baa2e4c24da9abc61fd1bed983b9026ba2e0f81746ac8070357b50f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The entertainment company will exit the Nasdaq after it completes its merger with Paramount Skydance.",
                "category": "company",
                "datetime": 1790937780,
                "headline": "Warner Bros. Stock Is About to Leave the Nasdaq. Here’s What’s Replacing It."
              },
              {
                "id": 142583452,
                "url": "https://finnhub.io/api/news?id=eab90e8a1a90a594c313b5bd453dcb55bc2f0107681411251c1018629c541b73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Twilio stock will join the benchmark S&P 500 index before the open on Oct. 6, replacing Warner Bros. Discovery.",
                "category": "company",
                "datetime": 1790935165,
                "headline": "Twilio To Join S&P 500 Index"
              },
              {
                "id": 142583147,
                "url": "https://finnhub.io/api/news?id=f08b5832d0ce0d643655c3688a93ed7e0e7d08cac40d0148895f3bb2f4d028bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Nike slumps after the retailer misses analysts’ first-quarter earnings target and issues downbeat full-year guidance.",
                "category": "company",
                "datetime": 1790934660,
                "headline": "Nike, ON Semi, Moderna, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142579892,
                "url": "https://finnhub.io/api/news?id=b0433938a5153602f02557a4aa3ac9dba90df0c0707dfef81c5471331dcce542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On Stocktwits, retail sentiment toward SPY and QQQ remained ‘bullish’ ahead of jobs data.",
                "category": "company",
                "datetime": 1790929901,
                "headline": "Nasdaq, S&P 500, Dow Futures Rise Ahead Of Jobs Report: NKE, META, RKLB, MRNA, SLS, TSLA Stocks In Focus"
              },
              {
                "id": 142585582,
                "url": "https://finnhub.io/api/news?id=33105858c73d24ffa69d7314514aa04fa9df16d5b28f255dd608b8dc69a9abdd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2169358315/image_2169358315.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Nike’s China slump is getting harder to outrun. Moderna is joining the Nasdaq-100. The mortgage industry is bracing for a credit-reporting shake-up.",
                "category": "company",
                "datetime": 1790924700,
                "headline": "Wall Street Breakfast Podcast: No Sprint For Nike Yet"
              },
              {
                "id": 142577980,
                "url": "https://finnhub.io/api/news?id=083d8ff77c6d7b8f8e91203788d831097d2ba90b023af25841e058696282e88f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.",
                "category": "company",
                "datetime": 1790924523,
                "headline": "SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot"
              },
              {
                "id": 142572008,
                "url": "https://finnhub.io/api/news?id=083eb6300141fad73672a0f96edcaff05674be5e6054f0a6ed58fabf49ef7015",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A longer shortage seems like great news for the flash memory specialist. Why did the stock hardly move?",
                "category": "company",
                "datetime": 1790913482,
                "headline": "Micron Says Memory Supply Will Be Much Tighter in 2028. Sandisk's Contracts Limit How Much It Can Gain."
              },
              {
                "id": 139935004,
                "url": "https://finnhub.io/api/news?id=577316ba7e18ee8a58031e18818b297139c2a77b4086c8f38a2ecd502b673edf",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1790907840,
                "headline": "Shares of broader communication services stocks are trading higher amid a rebound in the overall market following last week's decline."
              },
              {
                "id": 142563927,
                "url": "https://finnhub.io/api/news?id=408857fbe41844a63d7c191491d38d1b046b6f399c028e9883ac9d2f9e249c48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, of",
                "category": "company",
                "datetime": 1790899200,
                "headline": "Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026"
              },
              {
                "id": 142562988,
                "url": "https://finnhub.io/api/news?id=f5bbdb8f4ae66bda729818f8275385f5f21021cea9a2b9431c555e9d3361d95e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) closed the most recent trading day at $188.94, moving 1.89% from the previous trading session.",
                "category": "company",
                "datetime": 1790887805,
                "headline": "Moderna (MRNA) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 142562989,
                "url": "https://finnhub.io/api/news?id=87f52e78ca0d8ccab73f60658fea15421ce2a674c7f5064cb48cbd8f1213d931",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Check out the companies making headlines yesterday:",
                "category": "company",
                "datetime": 1790887507,
                "headline": "Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet"
              },
              {
                "id": 142561001,
                "url": "https://finnhub.io/api/news?id=337ede56bec87722f6079558d6a658f1e144fb7900c51f6aac31341c714ec6e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.",
                "category": "company",
                "datetime": 1790871390,
                "headline": "After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move"
              },
              {
                "id": 142562919,
                "url": "https://finnhub.io/api/news?id=1fbd8e26de53dbf149d1347b293aa371833389e270ea042e9abe496c51f0a778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.",
                "category": "company",
                "datetime": 1790868417,
                "headline": "Why Citi Is Sounding the Alarm on Moderna Stock"
              },
              {
                "id": 142559760,
                "url": "https://finnhub.io/api/news?id=8f361b2eb02af46d7061280f4e60d7ffa0b2f309294d3963a2bdce903cc74845",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.",
                "category": "company",
                "datetime": 1790866811,
                "headline": "Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water"
              },
              {
                "id": 142589128,
                "url": "https://finnhub.io/api/news?id=f79ed1c58cd6a10340417b1014aaa33aba6e3696bad04590f9f25b39986a7e29",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/01/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna Inc (NASDAQ:MRNA) shares are trending Thursday as the stock continues working through volatility following a bearish Citi downgrade earlier this week.",
                "category": "company",
                "datetime": 1790861443,
                "headline": "Moderna Stock Is Trending: What's Going On?"
              },
              {
                "id": 142557769,
                "url": "https://finnhub.io/api/news?id=716457aa4c02c97192c6401e34f80d7738cf68c917c0e25ebdf4355934fe2220",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?",
                "category": "company",
                "datetime": 1790856059,
                "headline": "Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz"
              },
              {
                "id": 142540767,
                "url": "https://finnhub.io/api/news?id=354f01ab3ffb52f17fffa0baf0e02019c8c004112604de1a2c35b6845f67ceca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "AI demand, stronger growth targets and index inclusion fuel a standout month for the enterprise-storage company.",
                "category": "company",
                "datetime": 1790839084,
                "headline": "Everpure Stock Is September’s Surprise S&P 500 Winner, Surging More Than 40% As Retail Piles In"
              },
              {
                "id": 142540770,
                "url": "https://finnhub.io/api/news?id=7c9329fd8dc60283c532920752d56c5581bb7d7c319ee20a0a1c5430387ceec2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "New investors might be eager to jump in during a bull market.",
                "category": "company",
                "datetime": 1790838300,
                "headline": "If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's This"
              },
              {
                "id": 142540765,
                "url": "https://finnhub.io/api/news?id=7d6465b472d118677c03014527a5f47cd568772afebdfde05f26b16e70df37cb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440523601/image_1440523601.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.",
                "category": "company",
                "datetime": 1790825460,
                "headline": "The Top HealthTech Questions Landing On Our Desks"
              },
              {
                "id": 142524865,
                "url": "https://finnhub.io/api/news?id=222ba29da438d1aab5a1d74e6c762d213e441897ce1585bfec5432cd76c60767",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.",
                "category": "company",
                "datetime": 1790806620,
                "headline": "Citi delivers major verdict after Moderna’s remarkable 703% run"
              },
              {
                "id": 142524132,
                "url": "https://finnhub.io/api/news?id=99b644c4dbe7656e77f51ec70027d88d044f33bbf2754173679e66718fbea76e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.",
                "category": "company",
                "datetime": 1790802073,
                "headline": "Why Moderna (MRNA) Shares Are Falling Today"
              },
              {
                "id": 142530199,
                "url": "https://finnhub.io/api/news?id=2e2d6f9e88c3b166b392e28c77871880c87b2f2ccc130062ab3138f10abf5510",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.",
                "category": "company",
                "datetime": 1790800857,
                "headline": "This Analyst Just Downgraded Moderna Stock. Here's Why."
              },
              {
                "id": 142524101,
                "url": "https://finnhub.io/api/news?id=c4a24a8a74cef8fdfe88fdb4b52791e7d289346eb6fb12519590d0f456753d02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.",
                "category": "company",
                "datetime": 1790799300,
                "headline": "Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline"
              },
              {
                "id": 142524124,
                "url": "https://finnhub.io/api/news?id=c6f5e4ce836a530ae05b8f89192a088e9bb36d545cf4712cabe9b1742ebf8167",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s stock has been flying high lately. That has one group of analysts saying it’s time to sell.",
                "category": "company",
                "datetime": 1790796699,
                "headline": "Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year"
              },
              {
                "id": 142522865,
                "url": "https://finnhub.io/api/news?id=8a521ce98bf09f06ab4f7dd8cd0e70efbf53ce3d9691b0291f356bcff2bca6f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company could enter a fresh growth phase.",
                "category": "company",
                "datetime": 1790792700,
                "headline": "Prediction: Moderna Stock Will Soar 100% by 2030"
              },
              {
                "id": 142522006,
                "url": "https://finnhub.io/api/news?id=124db892933c23eb411cf344af13765d8a1ce075a2e36ce66e707b17db28ac6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S",
                "category": "company",
                "datetime": 1790790030,
                "headline": "Sector Update: Healthcare Stocks Softer Wednesday Afternoon"
              },
              {
                "id": 142521986,
                "url": "https://finnhub.io/api/news?id=9cc9bac25ab6f4b0cc77442bcc076f9dfa4abbaf139a9918132c7658d38d8900",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.",
                "category": "company",
                "datetime": 1790789400,
                "headline": "Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142521984,
                "url": "https://finnhub.io/api/news?id=9a7b4bca9b1a4309d6a925cc89baefdfbbb69cd7ecf668d5abdfc06493049831",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Today, Sept. 30, 2026, softer PCE growth is supporting sentiment amid heightened single-stock volatility.",
                "category": "company",
                "datetime": 1790786373,
                "headline": "Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings"
              },
              {
                "id": 142558956,
                "url": "https://finnhub.io/api/news?id=98b77ff267649235f99bfe9517909b9a72de001c8ab02f5564afb6238e23b830",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/image.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "A key trading signal flashed for Moderna shares at a price of $186.46, after which MRNA rose over 3% to an intraday high.",
                "category": "company",
                "datetime": 1790782109,
                "headline": "Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal"
              },
              {
                "id": 142522031,
                "url": "https://finnhub.io/api/news?id=63454becd4abb8682a7c6937f2784e56df98e658bfd714754092494ebe7559ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.",
                "category": "company",
                "datetime": 1790782080,
                "headline": "Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter"
              },
              {
                "id": 142522033,
                "url": "https://finnhub.io/api/news?id=0c7f11fc2e27afae3e335037102ba549b3d2f5e4fb450b1c5af9210de361c233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.",
                "category": "company",
                "datetime": 1790780460,
                "headline": "Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?"
              },
              {
                "id": 142519813,
                "url": "https://finnhub.io/api/news?id=17ec7e19223b3ea07ff36979b275faa1c28e02702f7b5ca9bafd798374df9a48",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.",
                "category": "company",
                "datetime": 1790778901,
                "headline": "Wednesday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 142520851,
                "url": "https://finnhub.io/api/news?id=2c75b84a8e3ed43d9ef0b377df0785ea40960d26eccc6c99c516b20b5a6e7982",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.",
                "category": "company",
                "datetime": 1790777121,
                "headline": "After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst"
              },
              {
                "id": 142557492,
                "url": "https://finnhub.io/api/news?id=a38ca6bac6dfbfa01fd8d63f7e92381f6949b3d2aca9a04d8fc67da8d0602cf7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Augsburg--Bavaria--Germany---March-21--2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna stock dips as Juan Andres returns as COO, Jerh Collins retires, and the company expands its vaccine and cancer therapy portfolio.",
                "category": "company",
                "datetime": 1790776712,
                "headline": "What's Going On With Moderna Stock on Wednesday?"
              },
              {
                "id": 142517577,
                "url": "https://finnhub.io/api/news?id=ce2eba22449a0950f1937137a8d491338f3c95da529f8f44a9d9078f6136566f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.",
                "category": "company",
                "datetime": 1790775737,
                "headline": "Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat"
              },
              {
                "id": 142516715,
                "url": "https://finnhub.io/api/news?id=b78db5872e9430cf81361761ac090e11ce8cc09e85964919ae84b1e8fe38298b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Here's the market action in the first few minutes of trading.",
                "category": "company",
                "datetime": 1790775686,
                "headline": "Tech leads stocks higher after cooler-than-expected inflation read: AlphaCheck"
              },
              {
                "id": 142516721,
                "url": "https://finnhub.io/api/news?id=bb76bfa794beae6cf0c08bb55b649b68e623d691b44b38b410869e1cd7ac6654",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Target upgraded, Moderna downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1790775637,
                "headline": "Target upgraded, Moderna downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 142521661,
                "url": "https://finnhub.io/api/news?id=7dfb5fc4b59dcc4a8093306c5dc82aac44f9203c428f8ea5e1dfd69c02e5984c",
                "image": "https://image.cnbcfm.com/api/v1/image/108160476-1750176503101-gettyimages-2195142971-AFP_36VX2TG.jpeg?v=1750176587&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1790773473,
                "headline": "Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more"
              },
              {
                "id": 142520852,
                "url": "https://finnhub.io/api/news?id=28e32e8ee7e005ddb76aeb14811a95e1ad01c6a5c256b8356069e328e95e0a6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.",
                "category": "company",
                "datetime": 1790773380,
                "headline": "Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142557262,
                "url": "https://finnhub.io/api/news?id=a614fe6381c28affd2154cd1bd5af99d4a2c067b58bcf01e81cb808d167a27b7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Market-up.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.",
                "category": "company",
                "datetime": 1790772460,
                "headline": "Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today"
              },
              {
                "id": 142514612,
                "url": "https://finnhub.io/api/news?id=801733cd046f8895ae07f10d68920280f8c38957ffa7722c3ff0f9406b4e9dc7",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1790771701,
                "headline": "These S&P500 stocks are moving in today's pre-market session"
              },
              {
                "id": 142516716,
                "url": "https://finnhub.io/api/news?id=fa47ec443f59963c3625e8ac707d08d8347ac5b0f28491dd28769751e1a9eb0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.",
                "category": "company",
                "datetime": 1790771280,
                "headline": "Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell."
              },
              {
                "id": 142516123,
                "url": "https://finnhub.io/api/news?id=56f0c9ece7c01ec1810bcdd9f0956f5945caa2a7ec838f66a7edb7e950e41596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.",
                "category": "company",
                "datetime": 1790769808,
                "headline": "MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum"
              },
              {
                "id": 142514091,
                "url": "https://finnhub.io/api/news?id=e036cb6cd4e709f0ee5df941cc8cdbbc7ee0352453225fcf768171476633a090",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to AI infrastructure. Find out who got cut and who got a fresh vote of confidence.",
                "category": "company",
                "datetime": 1790769772,
                "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More"
              },
              {
                "id": 142514509,
                "url": "https://finnhub.io/api/news?id=d453f3fca1bb271c8cdcc1040b547798149c0df96d89bf797ac75570ced675b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com - U.S. stock index futures hovered around the flatline on Wednesday, as investors turned their focus to key inflation data closely watched by the Federal Reserve and upcoming earnings from semiconductor group Micron.",
                "category": "company",
                "datetime": 1790769760,
                "headline": "Premarket movers: Micron; Boeing rises, Moderna slides"
              },
              {
                "id": 142513401,
                "url": "https://finnhub.io/api/news?id=428e3ee65a54a0f1807a6866965d48388f9d7c07323eebf08087bba21fafcaab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "September turned out to be a mediocre month for S&P 500 investors. But some stocks wound up having a great month.",
                "category": "company",
                "datetime": 1790767008,
                "headline": "9 Stocks Turn $100,000 to $18.8 Million In 9 Months"
              },
              {
                "id": 142513402,
                "url": "https://finnhub.io/api/news?id=421cb7c8d9b76c06fa0af16c3bfcd6c97f288280a12c52c90990b5680ea17020",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ModernaCAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company.The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader onco",
                "category": "company",
                "datetime": 1790766000,
                "headline": "Moderna Adds Chief Operating Officer Role as Company Expands into Oncology"
              },
              {
                "id": 142518055,
                "url": "https://finnhub.io/api/news?id=7a8192e58a3b3a7f76cd5eef12a43346641a768e5368f3d70e29291f6586565e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Analyst-Woman-Working-With-Information-D.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and price targets.",
                "category": "company",
                "datetime": 1790758489,
                "headline": "This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday"
              },
              {
                "id": 142518071,
                "url": "https://finnhub.io/api/news?id=041ce0be0a643171ac19f00a1141def7d415225ccbea4606a57c39f085b5ab50",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/New-York--Ny--Usa---July-5--2022-Microso.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.",
                "category": "company",
                "datetime": 1790756528,
                "headline": "Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 142517103,
                "url": "https://finnhub.io/api/news?id=ec01469ed1b12fef0eee46bc0b7d5b42adffd92b6cedbc235e7a87e19f0a001a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Concentrix plunged 10.6% premarket after weak guidance, despite an earnings beat; several other stocks also traded lower.",
                "category": "company",
                "datetime": 1790755329,
                "headline": "Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session"
              },
              {
                "id": 142520287,
                "url": "https://finnhub.io/api/news?id=a26fb742864fb294a617a295d45aa831f088eb4a5de69f6df7152402478047fd",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Citigroup  analyst Geoff Meacham   downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $60 to $80.",
                "category": "company",
                "datetime": 1790749371,
                "headline": "Citigroup Downgrades Moderna to Sell, Raises Price Target to $80"
              },
              {
                "id": 142498243,
                "url": "https://finnhub.io/api/news?id=eaf88aabaf598a4b569b275c120d8333e97469795bff83e81d797cb0df79770a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1790691842,
                "headline": "2 S&P 500 Stocks to Consider Right Now and 1 We Question"
              },
              {
                "id": 142520288,
                "url": "https://finnhub.io/api/news?id=9633abfaab94223f2f7d4b1b79b777ba6af380f9513f184fc66cd521ecbf226b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/29/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are climbing again Tuesday, touching a new 52-week high of $208.90 on continued momentum from strong clinical trial news.",
                "category": "company",
                "datetime": 1790689372,
                "headline": "Moderna Sets Another Fresh 52-Week High: What's Happening?"
              },
              {
                "id": 142498625,
                "url": "https://finnhub.io/api/news?id=b078ce9932311c0ec1ff3a2786143129d201366a0e8b160b070fcaafb45008a3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna (MRNA) valuation update: stock near bull-case range but central-case implies downside.",
                "category": "company",
                "datetime": 1790684744,
                "headline": "Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion"
              },
              {
                "id": 142492403,
                "url": "https://finnhub.io/api/news?id=b967d0a35b5431fd5b8cffdaaf7884a4c26d1cc96c7ca1d751cd2988d8d20731",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "A new U.S. government award has Navitas shares surging. After a string of acquisitions, Lilly is hunting for its next big bet. A judge keeps a high-stakes mRNA patent battle alive.",
                "category": "company",
                "datetime": 1790665500,
                "headline": "Wall Street Breakfast Podcast: Federal Boost For Navitas"
              },
              {
                "id": 142490867,
                "url": "https://finnhub.io/api/news?id=c82e47177ec47c228cd214f7db9f0ddd5bd56908469c079373e137e8ea63b728",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385299308/image_1385299308.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "U.S. equity markets were mixed this week, with technology and growth-related areas leading, while several defensive and rate-sensitive sectors moved lower. Read more here...",
                "category": "company",
                "datetime": 1790663400,
                "headline": "ValuEngine Weekly Commentary: Sector And ETF Performance"
              },
              {
                "id": 142468210,
                "url": "https://finnhub.io/api/news?id=10bcce59937ac1418a643aba0249cd818e72deaaeb7421946fa3f52d33793650",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.",
                "category": "company",
                "datetime": 1790606890,
                "headline": "Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?"
              },
              {
                "id": 142464503,
                "url": "https://finnhub.io/api/news?id=27c7414fb6603d9617ca86e3afb46098324b65b0ddda4f5ef726ec4e93b36535",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.",
                "category": "company",
                "datetime": 1790598901,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Monday."
              },
              {
                "id": 142461417,
                "url": "https://finnhub.io/api/news?id=6820c9f6407798b076ea93b6a1419e9ed2df02adcb5ac40c752f2a523ae55b6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.",
                "category": "company",
                "datetime": 1790582342,
                "headline": "MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data"
              },
              {
                "id": 142453485,
                "url": "https://finnhub.io/api/news?id=7253a155a1abccf3f02ea05505082170326df6ff9ce1ed32b30bd1d051af5019",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investors rewarded companies with strong artificial intelligence demand, enterprise infrastructure, and drug development.",
                "category": "company",
                "datetime": 1790570877,
                "headline": "Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?"
              },
              {
                "id": 142442375,
                "url": "https://finnhub.io/api/news?id=f7beabea857cc096ec908c64340a034ef7bfdd0d253291b387964aa1850a6890",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...",
                "category": "company",
                "datetime": 1790471463,
                "headline": "Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks"
              },
              {
                "id": 142442405,
                "url": "https://finnhub.io/api/news?id=d779fc7c3a0c01111ed04f0ac724d330dba4fcdf419b309f2a63b11ae1675448",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...",
                "category": "company",
                "datetime": 1790467912,
                "headline": "Moderna (MRNA) Held Investment Talks With The UAE Government"
              },
              {
                "id": 142436697,
                "url": "https://finnhub.io/api/news?id=8db58902f8a901e02142333e7092ccad903b8ead626c0ca0d7858ec1a754c93b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242931384/image_2242931384.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "U.S. stocks advanced for the week while Treasury yields surged and petroleum markets remained in focus. Read more about this week's major events on Wall Street.",
                "category": "company",
                "datetime": 1790411148,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 142426214,
                "url": "https://finnhub.io/api/news?id=4cfaf03b327dd5f2dd7a1ff3a1d6b16df86fa095ae126d88a08c02add4523851",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.",
                "category": "company",
                "datetime": 1790369403,
                "headline": "Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing"
              },
              {
                "id": 142425625,
                "url": "https://finnhub.io/api/news?id=82e7b12bd7d88d0bae1a6ea3f20d9898a848ef5ecb4dfdf2264916ad9e6b23ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.",
                "category": "company",
                "datetime": 1790361434,
                "headline": "MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?"
              },
              {
                "id": 142424923,
                "url": "https://finnhub.io/api/news?id=2a6418f2dd1a1ca87c029dd8f1954d5f9d7e7a13b728f8a4a89ed70f03fc8908",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dow, Nasdaq, and S&P 500 all gain ground despite climbing bond yields, with AI stocks leading the charge, today, Sept. 25, 2026.",
                "category": "company",
                "datetime": 1790354418,
                "headline": "Stock Market Midday, Sept. 25: AI Momentum Lifts Markets as Akamai Soars on Anthropic Deal"
              },
              {
                "id": 142437418,
                "url": "https://finnhub.io/api/news?id=dfa8159d12fc0412e2cb85b1e5eb94182b5cb2d20337c25ada68b6e91db2712b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/25/Shanghai-china-nov-22nd-2025-Amd-Company.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.",
                "category": "company",
                "datetime": 1790352125,
                "headline": "AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street"
              },
              {
                "id": 142424869,
                "url": "https://finnhub.io/api/news?id=2850530e7bfac77eb273b56b0a9208715941d62e8197fa679600f877f4a54e5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.",
                "category": "company",
                "datetime": 1790350740,
                "headline": "Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts."
              },
              {
                "id": 142437867,
                "url": "https://finnhub.io/api/news?id=c4a3d47368e5f9e41451f69539c75664435647ce70caeac43325fa7e467e0f3d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/25/Kyiv--Ukraine---December-01--2020-Modern.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.",
                "category": "company",
                "datetime": 1790336838,
                "headline": "Moderna Stock Reached New 52-Week High: What's Happening?"
              },
              {
                "id": 142405801,
                "url": "https://finnhub.io/api/news?id=006838f8ced6332dc0acba2379725c751ab2aef9e4f253b26366c5d6e4cd9e3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.",
                "category": "company",
                "datetime": 1790312824,
                "headline": "Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24."
              },
              {
                "id": 142392963,
                "url": "https://finnhub.io/api/news?id=70f140ccdd3ef73bfe1021f5281a43c699cb88dc3919b70c5378fbbb27e02a74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.",
                "category": "company",
                "datetime": 1790306616,
                "headline": "MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better"
              },
              {
                "id": 142390040,
                "url": "https://finnhub.io/api/news?id=c7960b8bc529353866cfac1d931c119daf2ef705acaf37b2e27770dec14a2537",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]",
                "category": "company",
                "datetime": 1790297219,
                "headline": "Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak"
              },
              {
                "id": 142422582,
                "url": "https://finnhub.io/api/news?id=fbc9838e531ba43f45d575ddcff2068fabaa496d053644d7382d769e95e153f1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/25/Moderna-Sign-With-Bold-Red-3D-Lettering-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.",
                "category": "company",
                "datetime": 1790290473,
                "headline": "Why is Moderna (MRNA) Stock Trending After Hours?"
              },
              {
                "id": 142387772,
                "url": "https://finnhub.io/api/news?id=6d1f929b6e1003bb063ccf91eb7dd8f124e97a3267139c015926ec398eb0f9f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock was most recently helped by the company CEO’s optimism on its potential outside of COVID vaccines.",
                "category": "company",
                "datetime": 1790289671,
                "headline": "From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done"
              },
              {
                "id": 142384840,
                "url": "https://finnhub.io/api/news?id=440ff8c8146dd867e58e55182333f3e6978aa8b46089c7079aa9a7ea332040fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.",
                "category": "company",
                "datetime": 1790265360,
                "headline": "Moderna's View of the Global Pharma Industry"
              },
              {
                "id": 142367218,
                "url": "https://finnhub.io/api/news?id=9aaf68e15d0065775a974bc9e14980dc6719bbe61d03873d66b7863e26a04c51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Meta Platforms, Moderna and Okta rallied to fresh 52-week highs on Wednesday amid positive company catalysts and improving investor sentiment.",
                "category": "company",
                "datetime": 1790221966,
                "headline": "Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?"
              },
              {
                "id": 142364160,
                "url": "https://finnhub.io/api/news?id=f60528ea6c067597ae132ae73d0b61262326523dc883c9700c5efb29ee1c5b86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.",
                "category": "company",
                "datetime": 1790186400,
                "headline": "Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines"
              },
              {
                "id": 142363409,
                "url": "https://finnhub.io/api/news?id=b99c3da50eb2762f1f75c841babdbfef81ee5d40dbf1a25fb817ae6b038ec773",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Twilio climbed to multi-year highs on Wednesday, fueled by optimism around Moderna’s broader mRNA pipeline and Twilio’s emerging opportunity from the rapid adoption of AI agents.",
                "category": "company",
                "datetime": 1790186087,
                "headline": "These 2 Stocks Are Bucking The Broader Market Selloff To Hit New Multi-Year Highs — Here’s What’s Driving The Enthusiasm"
              },
              {
                "id": 142361985,
                "url": "https://finnhub.io/api/news?id=7a43d0ea90dc5d3eeda494c02a512c975b8a553410c726e640b84d38fbc58a3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office",
                "category": "company",
                "datetime": 1790175751,
                "headline": "Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID"
              },
              {
                "id": 142362610,
                "url": "https://finnhub.io/api/news?id=42c94a8dae1e73f70228a04c1203555497d39237b8ebb7d6ff7a4420e4a479b1",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 8:50 AM EDTCompany...",
                "category": "company",
                "datetime": 1790167169,
                "headline": "Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript"
              },
              {
                "id": 142358803,
                "url": "https://finnhub.io/api/news?id=87962f9bb4b6eb0c25e3cfa1c05685a4b675d266644338f9cd62473a6e65ac29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.",
                "category": "company",
                "datetime": 1790166480,
                "headline": "6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards"
              },
              {
                "id": 142356799,
                "url": "https://finnhub.io/api/news?id=034d8b2b6aa966fa6d6b73fb0cdaae8497b33158ca3ff07e66397ac36760b3fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.",
                "category": "company",
                "datetime": 1790163778,
                "headline": "Analysts Think 6 S&P 500 Stocks Are Grossly Overvalued"
              },
              {
                "id": 142360123,
                "url": "https://finnhub.io/api/news?id=2e5802cba842297d796bff6bf5332c96000c6054e89c8ad89fff63b599e27270",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/23/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.",
                "category": "company",
                "datetime": 1790157779,
                "headline": "TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday"
              },
              {
                "id": 142353012,
                "url": "https://finnhub.io/api/news?id=062ef42604487f6fb1b989b1073c300436bb966441f11a9b3372f4e2384085c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.",
                "category": "company",
                "datetime": 1790142300,
                "headline": "These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right."
              },
              {
                "id": 142353011,
                "url": "https://finnhub.io/api/news?id=12bf23b864a1c4b5e6f8678f4beb46231b8d3a6000422a28d6470fe6e1aec818",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...",
                "category": "company",
                "datetime": 1790138022,
                "headline": "Moderna (MRNA) Tied To AI Drug Push As Bob Langer Takes New Advisory Role"
              },
              {
                "id": 142350448,
                "url": "https://finnhub.io/api/news?id=11a8507335ac02a71f8a9b3e7e26acbd9438c009db1f20e9f41272daa3128600",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...",
                "category": "company",
                "datetime": 1790129574,
                "headline": "Moderna (MRNA) Stock Looks Very Expensive As Shares Surge Over 1 Year"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 241,
            "discarded_article_count": 200
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 3,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日5日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 16523006.666666666,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 20017660,
              "avg_vol_20": 18240780,
              "avg_vol_30": 16523006.666666666,
              "range_pct_10": 0.2469844245953038,
              "range_pct_20": 0.30564271888927025,
              "range_pct_30": 0.46228514984893293,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.211502264922728,
              "dist_to_20d_high": 0.0008666804600552479,
              "down_shrink_days": 1,
              "breakout_level_20d": 242.28999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.5342685670868168
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 7.962698215774139,
              "turnoverUsdM": 4066.213678233966,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 203.5278,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 15.9,
            "take_profit_price": 298.6232,
            "target_multiplier": 2.2,
            "technical_strength": 2,
            "take_profit_percent": 23.4
          },
          "positionPoints": 1.1,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.5599999999999998,
          "stopLossPercent": 15,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 19.2761,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 7.96
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 138.17
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2601
    },
    "kdj": {
      "d": 77.3,
      "j": 91.45,
      "k": 82.02,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 70.91
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 311970683,
      "recentSlope": 11498418.3,
      "previousSlope": 1983050
    },
    "rsi": 66.75,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 10,
      "trend": "上升",
      "value": 208.92,
      "position": "SAR由上轉下+趨勢強",
      "distancePct": 13.7,
      "previousTrend": "下降"
    },
    "ma50": 161.933,
    "macd": {
      "macd": 20.694529355748188,
      "trend": "強烈看漲",
      "signal": 19.94211499636074,
      "histogram": 0.7524143593874477
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 205.6597,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 24
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.94,
      "score": 4,
      "avgVolume": 17878934,
      "currentVolume": 16796983
    },
    "derived": {
      "ma20": 206.8495,
      "ma50": 161.933,
      "prevClose": 226.89,
      "avgVolume10": 19817878,
      "avgVolume20": 17878934,
      "changePercent": 6.69,
      "avgVolumeForScore": 17878934
    },
    "ma_cross": {
      "ma20": 206.8495,
      "ma50": 161.933,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 203.8735,
      "prevMa50": 158.2876,
      "spreadPct": 27.74,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 172.7455,
      "upper": 240.9535,
      "position": "上半部"
    },
    "rsi_short": 71.69,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.94
    }
  }
}

{
  "close": 242.08,
  "volume": 16796983,
  "changePercent": 6.69
}